EMA Grants PRIME Designation to MimeTech S.r.l. for Investigational Drug Udonitrectag Lysine in the Treatment of Diabetic Foot Ulcers (DFU)
We are proud to announce that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to our investigational drug, Udonitrectag lysine, for the treatment of diabetic foot ulcers (DFU). Existing measures for the treatment of diabetic foot ulcers achieve complete healing in only 30–60% of cases within six …